Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Evan Y. Yu, Jose Maria M. Piulats Rodriguez, Gwenaelle Gravis, Brigitte Laguerre, Jose Angel Arranz Arija, Stephane Oudard, Peter C.C. Fong, Michael Paul Kolinsky, Marinela Augustin, Tilman Todenhöfer, Audrey E. Kam, Howard Gurney, Ali Tafreshi, Margitta Retz, William R. Berry, Nataliya Mar, Haiyan Wu, Ping Qiu, Charles Schloss, Johann S. De Bono
Institutions: University of Washington, Institut Català d'Oncologia, Institut Paoli-Calmettes, Centre Eugène Marquis, Hospital General Universitario Gregorio Marañón, Hôpital Européen Georges-Pompidou, Auckland City Hospital, Cross Cancer Institute, Paracelsus Medizinische Privatuniversität, Rush University Medical Center, Macquarie University, University of Wollongong, TUM Klinikum, Technical University of Munich, Merck & Co., Inc., Rahway, NJ, USA (United States), Institute of Cancer Research, Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3031255294